Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE
January 23, 2019 08:06 ET
|
Attune Pharmaceuticals, Inc.
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics...
Attune Pharmaceuticals Announces Positive Phase 1 Results for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE
January 22, 2019 08:00 ET
|
Attune Pharmaceuticals, Inc.
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, a biotechnology company focused on the discovery and development of novel oral small molecule therapeutics for treatment of rare...
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
May 22, 2017 08:00 ET
|
Attune Pharmaceuticals, Inc.
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, a biotechnology company focused on the discovery and development of novel oral small molecule therapeutics for treatment of rare...
Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI
March 06, 2017 08:00 ET
|
Attune Pharmaceuticals, Inc.
NEW YORK, March 06, 2017 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, a biotechnology company focused on the discovery and development of novel oral small molecule therapeutics for treatment of rare...
Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE
March 01, 2017 08:00 ET
|
Attune Pharmaceuticals, Inc.
-- Poster Session 4213 on Monday, March 6 from 9:45 am to 10:45 am NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, a biotechnology company focused on the discovery and...